Terms: = Prostate cancer AND B2M, P61769, 567, ENSG00000166710 AND Treatment
35 results:
1. Partial gland ablation with high intensity focal ultrasound impact on genito-urinary function and quality of life: our initial experience.
Fugaru I; Bouhadana D; Marcq G; Moryousef J; Rompré-Brodeur A; Meng A; Loutochin O; Loutochin G; Anidjar M; Bladou F; Sanchez-Salas R
Can J Urol; 2024 Feb; 31(1):11784-11792. PubMed ID: 38401258
[TBL] [Abstract] [Full Text] [Related]
2. Hospitalizations Among Veterans Treated for Metastatic prostate cancer With Abiraterone or Enzalutamide.
Riekhof F; Yan Y; Bennett CL; Sanfilippo KM; Carson KR; Chang SH; Georgantopoulos P; Luo S; Govindan S; Cheranda N; Afzal A; Schoen MW
Clin Genitourin Cancer; 2024 Apr; 22(2):18-26.e3. PubMed ID: 37495480
[TBL] [Abstract] [Full Text] [Related]
3. Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification.
Yang X; Tan YG; Gatsinga R; Chen W; Huang HH; Loong JTK; Chua MLK; Rajasekaran T; Kanesvaran R; Tay KJ; Chen K; Yuen JSP
Int J Urol; 2023 Nov; 30(11):991-999. PubMed ID: 37431969
[TBL] [Abstract] [Full Text] [Related]
4. The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon.
Rakauskas A; Peters M; Ball D; Kim NH; Ahmed HU; Winkler M; Shah TT
Urol Oncol; 2023 Feb; 41(2):106.e9-106.e16. PubMed ID: 36564258
[TBL] [Abstract] [Full Text] [Related]
5. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
[TBL] [Abstract] [Full Text] [Related]
6. How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Urabe F; Kimura T; Sasaki H; Tashiro K; Iwatani K; Yasue K; Aoki M; Sato S; Takahashi H; Miki K; Egawa S
Int J Clin Oncol; 2022 Jan; 27(1):184-193. PubMed ID: 34599724
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of Several Pathways for Efficient Killing of prostate cancer Stem Cells: A Central Role of NF-κB RELA.
Witte KE; Pfitzenmaier J; Storm J; Lütkemeyer M; Wimmer C; Schulten W; Czaniera N; Geisler M; Förster C; Wilkens L; Knabbe C; Mertzlufft F; Kaltschmidt B; Am Esch JS; Kaltschmidt C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445612
[TBL] [Abstract] [Full Text] [Related]
8. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract] [Full Text] [Related]
9. Time pressure predicts decisional regret in men with localized prostate cancer: data from a longitudinal multicenter study.
Hilger C; Schostak M; Otto I; Kendel F
World J Urol; 2021 Oct; 39(10):3755-3761. PubMed ID: 34021406
[TBL] [Abstract] [Full Text] [Related]
10. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical prostatectomy.
Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
[TBL] [Abstract] [Full Text] [Related]
11. The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients.
Benoist GE; van Oort IM; Burger DM; Mehra N; van Erp NP
Cancer Chemother Pharmacol; 2020 Apr; 85(4):753-760. PubMed ID: 32076807
[TBL] [Abstract] [Full Text] [Related]
12. Automatic VMAT planning for post-operative prostate cancer cases using particle swarm optimization: A proof of concept study.
Künzel LA; Leibfarth S; Dohm OS; Müller AC; Zips D; Thorwarth D
Phys Med; 2020 Jan; 69():101-109. PubMed ID: 31862575
[TBL] [Abstract] [Full Text] [Related]
13. Contemporary national trends in prostate cancer risk profile at diagnosis.
Fletcher SA; von Landenberg N; Cole AP; Gild P; Choueiri TK; Lipsitz SR; Trinh QD; Kibel AS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):81-87. PubMed ID: 31235801
[TBL] [Abstract] [Full Text] [Related]
14. Long-term Somatic Disease Risk in Adult Danish cancer Survivors.
Kjaer TK; Andersen EAW; Winther JF; Bidstrup PE; Borre M; Møller H; Larsen SB; Johansen C; Dalton SO
JAMA Oncol; 2019 Apr; 5(4):537-545. PubMed ID: 30844031
[TBL] [Abstract] [Full Text] [Related]
15. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with prostate cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Shin SH; Choi H; Bae JH; Park JY
Cancer Res Treat; 2019 Apr; 51(2):593-602. PubMed ID: 30025445
[TBL] [Abstract] [Full Text] [Related]
16. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk prostate cancer Patients.
Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
[TBL] [Abstract] [Full Text] [Related]
17. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.
Lee KS; Koo KC; Chung BH
Int Urol Nephrol; 2017 Dec; 49(12):2119-2125. PubMed ID: 28905176
[TBL] [Abstract] [Full Text] [Related]
18. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):28-34. PubMed ID: 26754263
[TBL] [Abstract] [Full Text] [Related]
19. Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain.
Gómez Caamaño A; Zapatero A; López Torrecilla J; Maldonado X
Clin Transl Oncol; 2016 Sep; 18(9):884-92. PubMed ID: 26621508
[TBL] [Abstract] [Full Text] [Related]
20. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract] [Full Text] [Related]
[Next]
